Grades, scores, and FDA catalyst signals for Immunology stocks tracked by BiotechSign
| Ticker | Company | Score | Grade | Sector | Signals |
|---|---|---|---|---|---|
| UCBNV | UCB SA | 63 | C | Neurology Immunology | — |
| CABA | Cabaletta Bio | 59 | C | Immunology | — |
| NKTR | Nektar Therapeutics | 58 | C | Immunology | — |
| RIGL | Rigel Pharmaceuticals | 56 | C | Immunology | — |
| ABBV | AbbVie Inc | 52 | C | Immunology | — |
| SNY | Sanofi SA | 51 | C | Immunology | — |
| AIM | AIM ImmunoTech Inc. | 37 | D | Immunology | — |
| ALPN | Alpine Immune Sciences | 27 | F | Immunology | — |
| IMNM | Immunome, Inc. | 26 | F | Immunology | — |
| APGE | Apogee Therapeutics | 23 | F | Immunology | — |
| ANAB | AnaptysBio Inc | 22 | F | Immunology | — |
| GOSS | Gossamer Bio | 21 | F | Immunology/Oncology | — |
| ESLA | Estrella Immunopharma, Inc. | 21 | F | Immunology | — |
Autoimmune and inflammatory disease biotech targets conditions including rheumatoid arthritis, inflammatory bowel disease (IBD), psoriasis, lupus, atopic dermatitis, and multiple sclerosis. Large patient populations, proven commercial models (biologics like adalimumab and ustekinumab generated billions annually), and established regulatory pathways make approvals in this sector highly valuable. The JAK inhibitor class and next-generation IL-targeting biologics have driven significant innovation. PDUFA catalysts in immunology tend to be less binary than oncology or rare disease given more established endpoints and larger trials, but approval opens access to enormous addressable markets. Biosimilar competition to established agents creates headwinds for some incumbents and opportunities for innovators.